Ronald Martell is a veteran biopharmaceutical executive and serial entrepreneur, having founded five companies and served on the boards of directors of several others. In February 2022, Ronald became the CEO of Jasper Therapeutics, a biotechnology company focused on developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases.

Prior to joining Jasper, Ronald served as the President and CEO of MorphImmune, Inc., a private platform company advancing a highly specific targeting technology that uses a ligand-linked payload to reprogram the immune system. Previously, he was President and CEO of Nuvelution Pharma. He was also Co-Founder and Executive Chairman of Indapta, Orca Bio and Co-Founder and CEO of Achieve Life Sciences, where he led the merger of the company with Oncogenex. Ronald has served as the CEO of three public biopharmaceutical companies, including Sevion and NeurogesX, and has overseen billions of dollars in industry transactions.

Earlier in his career, Ronald served as Senior Vice President of Commercial Operations at ImClone Systems, where he was instrumental in deals with Bristol-Myers Squibb and Merck KGaA and built ImClone Systems’ worldwide operations to market and commercialize Erbitux®. He also served in various leadership positions with Genentech where, as Group Manager, Oncology, he was responsible for building the company’s oncology franchise, including the launch of Herceptin® and Rituxan®.

Ronald is passionate about leading public biopharmaceutical companies in all phases of development and maximizing their potential across the healthcare industry.

Mr. Mahal joined Jasper Therapeutics as Chief Financial and Business Officer from Portola Pharmaceuticals, where he worked for 11 years and held a number of positions of increasing leadership, most recently as Vice President, Business Development and Vice President, Strategic Marketing. He led the successful execution of multiple business development partnerships for Andexxa^®, Bevyxxa^® and cerdulatinib. He also played a key role in the company’s equity financings, including its initial public offering and multiple royalty transactions. Earlier in his career, he was Director, Business and New Product Development, at Johnson & Johnson on the Xarelto^® development and strategic marketing team. He started his career in the drug development laboratories at COR Therapeutics.

Edwin Tucker has over 30 years of clinical experience leading novel drug development. Dr. Tucker was most recently Chief Medical Officer at Goldfinch Bio, where he led clinical development and helped build the regulatory, medical affairs, and clinical operations functions. Previously he served as Chief Medical Officer at Mirum Pharmaceuticals, where he contributed to the achievement of key milestones in the development of medicines for adult and pediatric cholestatic liver disease including the first FDA approval for Alagille Syndrome. Prior to joining Mirum, Dr. Tucker was at Acerta Pharma LLC, now part of the AstraZeneca family of companies, ultimately serving as Chief Operating Officer. Prior to joining Acerta, he held leadership positions in development, medical safety and medical affairs at Genentech, Janssen Research and Development and Bayer HealthCare Pharmaceuticals.

Dr. Tucker is a member of the Royal College of Physicians (UK), and received his M.B.A. from the University of Connecticut. Dr. Tucker holds degrees in Pharmacology and Medicine from the University of Leeds, United Kingdom. Additionally, he serves as a managing director at Golden Seeds, an investment firm dedicated to pursuing early-stage investment opportunities in women-led businesses.

Herb Cross previously served as CFO at Atreca, leading its initial public offering and holding responsibility for all administrative functions, including finance, corporate communications, human resources and corporate services. Prior to Atreca, he was CFO at ARMO BioSciences, with responsibility for all administrative functions and business development, and led its initial public offering and served as CFO through the sale of the company to Eli Lilly in 2018. Mr. Cross also served as CFO and interim Chief Executive Officer at KaloBios Pharmaceuticals and was CFO at Affymax as well. Mr. Cross began his career at Arthur Andersen, LLP, and received a Bachelor of Science in Business Administration from the Haas School of Business at the University of California, Berkeley. He is a certified public accountant, currently inactive, in the state of California.

Dr. Pang joined Jasper with the Series A funding and has led early research and development, including leading creation of the company’s mRNA stem cell graft platform and playing a pivotal role in advancing JSP191 across multiple clinical studies. Prior to Jasper, Dr. Pang was an Instructor in the Division of Blood and Marrow Transplantation at Stanford University, where she had an active clinical practice and conducted translational research in hematology / oncology and stem cell biology. Prior to that, Dr. Pang was a Resident and Fellow in hematology at Stanford University School of Medicine. She was a Walter and Idun Berry Postdoctoral Fellow in the Judith Shizuru laboratory at Stanford University. She was the lead author on the proof-of-concept studies showing that an anti-CD117 antibody therapy targets disease-initiating human hematopoietic (blood cell-forming) stem cells in myelodysplastic syndrome (MDS). She was also a National Institutes of Health Regenerative Medicine Predoctoral Fellow in the Irving Weissman laboratory at Stanford University. She authored numerous publications on the identification and characterization of hematopoietic stem and progenitor cell behavior in aging, non-malignant hematopoietic diseases, as well as hematopoietic malignancies, including MDS and acute myeloid leukemia (AML). Dr. Pang has multiple patents and patent applications. Dr. Pang holds an MD and PhD in Cancer Biology from Stanford University, and master’s and bachelor’s degrees in Biology from Harvard University.

Patricia Carlos has over 25 years of experience in the biotech and pharmaceutical industry, with a proven track record of success in driving global strategy, regulatory affairs, and strategic partnerships. Her expertise spans early development through approval and post-marketing in multiple therapeutic areas. Prior to joining Jasper, she was Chief Regulatory, Quality and Safety Officer at Agenus, an immuno-oncology company. Previously, she served as Senior Vice President of Regulatory and Quality at Arcus Biosciences, where she built out the Regulatory, Quality and Safety functions and led the global regulatory strategy. Prior to Arcus, Patty held leadership roles at Bellicum Pharmaceuticals, BeiGene, Medivation-Pfizer, Gilead Sciences, and Bayer. Patricia received her bachelor’s degree from Memorial University of Newfoundland.

Dr. Di Noto joined Jasper Therapeutics in 2020 as Vice President, Technical Operations. He has extensive industry experience in process development, process scale-up, technology transfer, cGMP manufacturing, and regulatory submissions for biologic drugs. Before joining Jasper, he was at Portola Pharmaceuticals where he worked for five years as the Head of Drug Substance manufacturing, overseeing the Andexxa^® program. As a member of the Technical Operation Senior Leadership Team, Dr. Di Noto played a vital role in building a robust manufacturing program, developing a global contract manufacturing network strategy, and achieving successful approval of a second-generation version of Andexxa, both in the United States and Europe. Before joining Portola, Dr. Di Noto worked at Alexion Pharmaceuticals where he developed processes for many of its lead candidate drugs both in early and late stages of development. Prior to that, he worked at Amgen. Dr. Di Noto started his career at the National Institutes of Health where he was a Research Fellow at the National Heart, Lung and Blood Institute).

David Ku joined Jasper Therapeutics in 2020 and has led business development and finance, including leading Jasper’s partnerships with the NHLBI, NIAID and NCI institutes of the NIH as well as gene therapy partners at Graphite Bio and AVROBIO. He has supported the company’s financing, raising over $100M in new capital from taking Jasper public in 2021. In addition to corporate development, he now leads Jasper’s program team for briquilimab (JSP191) in chronic diseases and stem cell transplant for rare diseases.

Prior to Jasper, he worked at Gilead in strategic planning and at McKinsey as a consultant in the Life Sciences Practice. While at McKinsey, he served biotech and pharma clients on R&D strategy, portfolio management and asset evaluation. Dr. Ku received his M.D. with distinction from the Mount Sinai School of Medicine and S.B. in Computer Science from MIT.

Annette joined Jasper Therapeutics as Vice President, Clinical Operations after more than 30 years in senior clinical operations and development roles, leading large-scale clinical programs in complicated and novel therapeutic areas. Prior to Jasper, she served as Vice-President of Clinical Affairs at Neurogastrx, where she successfully progressed the NG101 program in Gastroparesis. Prior to Neurogastrx, she served as Vice-President of Clinical Operations at Aimmune, where she was a key figure in designing the clinical development program and implemented and managed the studies leading to the approval of the first-in-class peanut allergy treatment Palforzia™. At prior companies, she has been a key participant in the filings of several US and EU marketing applications and has held key leadership positions in programs that have directly contributed to successful product approvals and label expansions for multiple drugs and biologics. Over the past two decades, Annette has also provided consulting support to numerous bio-pharmaceutical companies to support their development programs, and in one case served as a client’s regulatory representative to the FDA. Annette received her Bachelor’s degree from Loyola-Marymount University and her MBA from University of Phoenix.

Matt Ford joined Jasper Therapeutics in 2023 as Vice President, Human Resources from Tricida Inc, where he was the Senior Vice President, HR & Operations. Prior to joining Tricida, he held various global HR leadership roles at Jazz Pharmaceuticals and Gilead Sciences.

Mr. Ford earned his Bachelor of Science degree in Biochemistry & Genetics from The University of Sheffield in the UK.